Transcat (NASDAQ:TRNS) Upgraded to “Strong-Buy” at Zacks Research

Transcat (NASDAQ:TRNS) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday, Zacks reports.

Other research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Transcat in a research note on Tuesday, August 25th. CJS Securities assumed coverage on shares of Transcat in a research report on Tuesday, October 27th. They set an “outperform” rating and a $115.00 price objective for the company. Northland Securities raised shares of Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 price objective on the stock in a research report on Wednesday, October 21st. Finally, Oppenheimer raised Transcat from a “market perform” rating to an “outperform” rating and set a $115.00 price target for the company in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $108.33.

Transcat Trading Up 1.1%

Shares of NASDAQ TRNS traded up $1.13 during midday trading on Thursday, reaching $101.51. 169,759 shares of the stock were exchanged, compared to its average volume of 135,380. The business has a 50-day simple moving average of $86.94 and a two-hundred day simple moving average of $82.43. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.49 and a quick ratio of 2.11. The company has a market capitalization of $953.18 million, a price-to-earnings ratio of 211.48 and a beta of 0.61. Transcat has a 12 month low of $50.23 and a 12 month high of $110.47.

Transcat (NASDAQ:TRNS) last posted its earnings results on Tuesday, November 3rd. The scientific and technical instruments company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.19. Transcat had a return on equity of 5.56% and a net margin of 0.99%. The firm had revenue of $97.09 million during the quarter, compared to analysts’ expectations of $92.46 million. As a group, equities research analysts expect that Transcat will post 2.06 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Jaime A. Irick bought 2,275 shares of the company’s stock in a transaction dated Thursday, November 5th. The stock was bought at an average price of $101.26 per share, with a total value of $230,366.50. Following the completion of the acquisition, the chief executive officer owned 2,275 shares of the company’s stock, valued at $230,366.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Integrated Wealth Concepts LLC acquired a new position in shares of Transcat during the 2nd quarter worth approximately $32,000. Persistent Asset Partners Ltd acquired a new stake in shares of Transcat in the second quarter valued at approximately $52,000. GAMMA Investing LLC raised its position in shares of Transcat by 133.6% in the third quarter. GAMMA Investing LLC now owns 1,030 shares of the scientific and technical instruments company’s stock valued at $91,000 after buying an additional 589 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Transcat in the second quarter valued at approximately $204,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Transcat in the second quarter valued at approximately $226,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

More Transcat News

Here are the key news stories impacting Transcat this week:

• Positive Sentiment: Zacks upgraded Transcat to Rank #1 (Strong Buy), citing improving earnings prospects, and included TRNS on its Strong Buy momentum-stock list. Zacks Strong Buy upgrade
• Positive Sentiment: Northland Securities raised its EPS forecasts across 2027–2031, including lifting its FY2027 estimate to $2.00 from $1.71 and its FY2031 estimate to $3.69 from $3.53. The revisions suggest stronger expected earnings growth. Northland estimate revisions
• Positive Sentiment: Oppenheimer raised its rating on Transcat to Outperform, adding to the favorable analyst sentiment. Oppenheimer rating upgrade
• Positive Sentiment: Recent coverage linked TRNS reaching a 52-week high to an earnings beat and improved outlook. The supplied background also reports quarterly EPS of $0.64 versus a $0.45 consensus estimate, with revenue above forecasts. Transcat 52-week high following earnings beat
• Neutral Sentiment: Northland maintained an Outperform rating but set a $95 price target, below the $101.32 share price cited in the background; this may temper the impact of its higher earnings forecasts. Northland rating and target

Transcat Company Profile

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.